Charles Schwab Investment Management Inc. Sells 112,434 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Charles Schwab Investment Management Inc. reduced its stake in Standard BioTools Inc. (NASDAQ:LAB) by 4.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,332,649 shares of the company’s stock after selling 112,434 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.63% of Standard BioTools worth $4,082,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in Standard BioTools by 2.3% in the 3rd quarter. Geode Capital Management LLC now owns 6,949,717 shares of the company’s stock valued at $13,415,000 after buying an additional 154,848 shares during the last quarter. Hollow Brook Wealth Management LLC bought a new stake in Standard BioTools in the 3rd quarter valued at about $10,679,000. State Street Corp grew its position in Standard BioTools by 26.7% in the 3rd quarter. State Street Corp now owns 5,495,136 shares of the company’s stock valued at $10,606,000 after purchasing an additional 1,157,984 shares during the period. Barclays PLC lifted its holdings in shares of Standard BioTools by 13.2% in the third quarter. Barclays PLC now owns 3,228,360 shares of the company’s stock valued at $6,231,000 after purchasing an additional 377,195 shares in the last quarter. Finally, Bradley & Co. Private Wealth Management LLC bought a new stake in Standard BioTools in the 4th quarter worth about $314,000. 53.74% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Casdin Partners Master Fund, L acquired 4,820,959 shares of the business’s stock in a transaction dated Friday, February 28th. The stock was purchased at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the acquisition, the director now owns 58,846,780 shares of the company’s stock, valued at $62,377,586.80. This trade represents a 8.92 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 53.10% of the company’s stock.

Standard BioTools Price Performance

Shares of NASDAQ:LAB opened at $1.19 on Thursday. The company has a market cap of $450.99 million, a price-to-earnings ratio of -1.68 and a beta of 1.62. Standard BioTools Inc. has a one year low of $0.99 and a one year high of $3.04. The firm has a fifty day moving average price of $1.35 and a two-hundred day moving average price of $1.69.

Wall Street Analyst Weigh In

Separately, KeyCorp downgraded Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.